S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Sanofi, Regeneron Get Positive News from Drug Trials (SNY, REGN)

Photo of Paul Ausick
By Paul Ausick Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this morning. The investigational drug, SAR236553/REGN727, reduced levels of LDL-C, or “bad,” cholesterol in 40%-72% of patients who were taking stable doses of statin drugs.

The drug could be important in helping patients reduce cholesterol levels further when they reach the limitations of what a statin drug can do, according to a press release.

The news has boosted Regeneron shares to a new 52-week high of $121.14, up more than 1%. Sanofy’s ADS are also up about 1% at $38.72.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Jon C. Ogg |

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more…
Chris Lange |

Have Analysts Fully Priced in Praluent to Regeneron?

ThinkstockRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA)…
Chris Lange |

How Amgen Can Disrupt the Market for Cholesterol Drugs

Amgen has the potential to disrupt the market for cholesterol drugs with the newest addition to its drug portfolio.
Will a PCSK9 Inhibitor Price Cut Help Drive Lowering LDL-Cholesterol Drug Use?
Jon C. Ogg |

Will a PCSK9 Inhibitor Price Cut Help Drive Lowering LDL-Cholesterol Drug Use?

Regeneron Pharmaceuticals and Sanofi are committing to lowering the price of the anti-cholesterol drug Praluent.
As Trump Cuts Drug Prices, These Are the 50 Most Prescribed Drugs In The US
Kristin Hitchcock |

As Trump Cuts Drug Prices, These Are the 50 Most Prescribed Drugs In The US

“The president is dead serious about lowering drug prices,” said one Whitehouse representative, commenting on President Trump’s commitment to slash…
3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential
Lee Jackson |

3 Biotech Stocks With Catalysts That Have 90% to 500% Upside Potential

The analysts at Stifel have noted three biotech companies that not only have data that could prove to be huge,…
Will New Marketing Push Pump Amarin Stock?
247sarah |

Will New Marketing Push Pump Amarin Stock?

Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the…
Gemphire Therapeutics Gears Up for IPO
Chris Lange |

Gemphire Therapeutics Gears Up for IPO

Gemphire Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Lee Jackson |

Why These 2 Biotech Stocks May Be Bought Out Soon

In a new report, Stifel sees two biotech stocks with near-term catalysts that could make takeover candidates soon.

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618